PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

This study tests whether an immunotherapy drug (tislelizumab) combined with an oral chemotherapy drug (S-1) helps patients with esophageal cancer who still have tumor cells at the primary site but no lymph node spread after surgery and pre-surgery treatment. The goal is to prevent the cancer from coming back. **You may be eligible if...** - You are 18–75 years old with esophageal squamous cell carcinoma - You received immunotherapy and chemotherapy before surgery, and after surgery your lymph nodes were clear but there was still some residual cancer at the original tumor site - You had a complete (radical) surgical removal of the tumor - You are in good physical condition (ECOG score 0 or 1) with no signs of recurrence **You may NOT be eligible if...** - You had another cancer within the past 5 years (with some exceptions) - You have had lung inflammation (interstitial lung disease) or needed steroids for pneumonia - You are currently taking systemic steroids or immune-suppressing drugs - You are severely allergic to fluorouracil chemotherapy or any monoclonal antibody - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.